Lee Ainslie Eli Lilly & CO Transaction History

Maverick Capital LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$525.19 - $619.13 $190,643 - $224,744	363 Added 22.15%	2,002 $1.17 Million
Q3 2023 Nov 14, 2023	BUY	$434.7 - $599.3 $712,473 - $982,252	1,639 New	1,639 $880,000
Q4 2021 Feb 14, 2022	SELL	$224.85 - $279.04 $748,975 - $929,482	-3,331 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$221.6 - $272.71 $406,192 - $499,877	1,833 Added 122.36%	3,331 $770,000
Q2 2021 Aug 16, 2021	BUY	$180.55 - $233.54 $270,463 - $349,842	1,498 New	1,498 $344,000
Q4 2020 Feb 16, 2021	SELL	$130.46 - $172.63 $697,830 - $923,397	-5,349 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$146.22 - $169.13 $782,130 - $904,676	5,349 New	5,349 $792,000

4,229

755M

9.22M

10.9M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $802B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Maverick Capital LTD, based on Form 13F filings with the SEC.

Stay updated on Maverick Capital LTD and Lee Ainslie with notifications on news.